FDA — authorised 23 November 2004
- Application: NDA021357
- Marketing authorisation holder: BRACCO
- Local brand name: MULTIHANCE
- Indication: INJECTABLE — INTRAVENOUS
- Status: approved
FDA authorised MULTIHANCE: on 23 November 2004
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 23 November 2004; FDA has authorised it.
BRACCO holds the US marketing authorisation.